Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $10 from $9 and keeps a Buy rating on the shares after the company reported a beat and raise quarter. Paysign is “in the early innings of an inflection in pharma revenues,” according to the analyst, who believes “investors should take note.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS: